AMRI wins UK Government contract
To develop an active pharmaceutical ingredient for clinical trials
AMRI's subsidiary, Albany Molecular Research (UK), based in Holywell, Wales, formerly Excelsyn, has been awarded a seven-year contract for the development and manufacture of an active ingredient for clinical trials.
The contract was awarded by the Defence Science and Technology Laboratory (Dstl), acting on behalf of the UK’s Secretary of State for Defence, the Department of National Defence of Canada and Minister of Defence of the Kingdom of the Netherlands.
AMRI will initially work on the development and scale-up of the investigational drug, and the manufacture and supply for Phase 1 clinical trials. If the trials are successful, AMRI may also become the commercial manufacturer of the product for distribution to the government partners in the contract.
'We are excited for the opportunity to work on this important project for the UK government,' said AMRI’s President and CEO, Thomas D’Ambra.
'Government contracts and related collaborations outside of our typical outsourcing contracts with biotechnology and pharmaceutical companies are part of our strategy to diversify our revenue base while making our high-quality services available to all industries, sectors and organisations that can benefit from our strengths in discovery, development and manufacturing.'
